NCT02314637

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 240 (actual)
• Sponsor: Tanabe Pharma Corporation · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients with type 2 Diabetes for 52 weeks administration.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Teneligliptin	Teneligliptin for 52 weeks
DRUG	Teneligliptin + Sulfonylurea	Teneligliptin for 52 weeks in combination with sulfonylurea

Timeline

• Start date: 2009-08-01
• Primary completion: 2011-07-01
• Completion: 2011-07-01
• First posted: 2014-12-11
• Last updated: 2026-01-05
• Results posted: 2015-01-02

Locations

1 site across 1 country: Japan